

## Drug Monograph

Drug/Drug     **Avar™ (sulfur and sulfacetamide sodium) Foam /**  
Class:         **Topical Anti-Acne Agents**  
Prepared for: MO HealthNet  
Prepared by: Xerox Heritage, LLC

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

<b>Purpose:</b>	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
<b>Dosage Forms:</b>	Avar™ is available as aerosol foam. Each gram contains 95 mg (9.5%) of sodium sulfacetamide and 50 mg of colloidal sulfur (5%).
<b>Manufacturer:</b>	Mission Pharmacal Company, San Antonio, TX 78230
<b>Indications:</b>	Avar™ foam is indicated for use in the topical control of acne vulgaris, acne rosacea, and seborrheic dermatitis.
<b>Costs:</b>	\$485 per 100 g container of Avar™. Wholesale Acquisition Cost
<b>Summary of Findings:</b>	The MO HealthNet Division recommends prior authorization status for this product.
<b>Status Recommendation:</b>	<input checked="" type="checkbox"/> Prior Authorization (PA) Required <input type="checkbox"/> Open Access <input type="checkbox"/> Fiscal Edit <input type="checkbox"/> PDL
<b>Type of PA Criteria:</b>	<input type="checkbox"/> Increased Risk of ADE <input type="checkbox"/> Non-Preferred Agent <input checked="" type="checkbox"/> Appropriate Indications <input type="checkbox"/> No PA Required

Prepared By: Luke Boehmer Pharm.D.  
Date: November 10, 2015